menu search

Biovie says blinded data points to hopeful alzheimer's treatment potential

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its ...

October 25, 2023, 2:19 pm

Pepgen announces presentations at the 2023 myotonic dystrophy foundation annual conference, ottawa neuromuscular disease meeting, and h.c. wainwright 25th annual global investment conference

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonu...

September 1, 2023, 8:00 am

Amarin highlights new data providing potential mechanistic insight into vascepa®/vazkepa® (icosapent ethyl) reduction of cardiovascular events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — –Data Further A...

May 12, 2023, 3:00 pm

Molecular partners to present additional preclinical data supporting the company’s radio darpin therapy platform at aacr

Targeted radionuclide delivery platform strengthened by new safety and mechanistic data Data includes r...

April 14, 2023, 5:00 am

Omeros: worst has been priced in, we like its igan pipeline, initiating with a buy

Omeros corporation's hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) should be considered a free option at this poin...

February 4, 2023, 8:33 am

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standa...

November 11, 2022, 5:00 pm


Search within

Pages Search Results: